Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Opioid Use Disorder · Opioid Dependence

Indivior Pty

Indivior Pty Ltd

Indivior Pty patent portfolio — 34 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
., Richmond, VA, US HQ
967 Employees
TGA registrant Type
Company details
Status
Public
HQ
., Richmond, VA, US
Employees
967
Programs
39
Drugs
19
Patents
34
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Indivior Pty patents

34 pharmaceutical patents indexed for Indivior Pty. 0 expire within 24 months.

Indivior Pty has 34 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

34 patents

Patent portfolio

  1. US 12290596

    Compositions and methods for the treatment of opioid overdose

    Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11839611

    Buprenorphine dosing regimens

    Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11712475

    Sustained delivery formulations of risperidone compound

    Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11135216

    Sublingual and buccal film compositions

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11110093

    Sustained release small molecule drug formulation

    Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11013809

    Sustained delivery formulations of risperidone compound

    Expires Mon May 20 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11000520

    Buprenorphine dosing regimens

    Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10654842

    Dopamine D3 receptor antagonist compounds

    Expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10646484

    Methods to treat opioid use disorder

    Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10592168

    Injectable flowable composition comprising buprenorphine

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10584135

    Substituted 3,6-diazabicyclo[3.2.0]heptanes

    Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10577361

    Dopamine D3 receptor antagonists having a morpholine moiety

    Expires Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10558394

    Injectable flowable composition comprising buprenorphine

    Expires Mon Feb 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10517864

    Sustained-release buprenorphine solutions

    Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10406160

    Sustained release small molecule drug formulation

    Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10376590

    Sustained delivery formulations of risperidone compound

    Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10273244

    Substituted hexahydropyrrolo[3,4-b]pyrroles and hexahydrocyclopenta[c]pyrroles as dopamine receptor modulators

    Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10239870

    Dopamine D3 receptor antagonists

    Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10198218

    Injectable flowable composition comprising buprenorphine

    Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10172849

    Compositions comprising buprenorphine

    Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10149912

    Dehydrated hydrogel inclusion complex

    Expires Mon Dec 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10058554

    Sustained release small molecule drug formulation

    Expires Mon Aug 23 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10022367

    Sustained-release buprenorphine solutions

    Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10010612

    Sustained delivery formulations of risperidone compounds

    Expires Mon Jun 28 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10000477

    Dopamine D3 receptor antagonist compounds

    Expires Mon Jun 14 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9827241

    Injectable flowable composition comprising buprenorphine

    Expires Mon Nov 23 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9782402

    Injectable composition comprising buprenorphine

    Expires Mon Oct 05 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9687454

    Sublingual and buccal film compositions

    Expires Mon Jun 22 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9498432

    Injectable flowable composition comprising buprenorphine

    Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9486531

    Dehydrated hydrogel inclusion complex of a bioactive agent with flowable drug delivery system

    Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9295645

    Compositions comprising buprenorphine

    Expires Mon Mar 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9272044

    Injectable flowable composition buprenorphine

    Expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9186413

    Sustained delivery formulations of risperidone compounds

    Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9180197

    Sustained delivery formulations of risperidone compounds

    Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Indivior Pty have?

34 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Indivior Pty patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.